Jade Biosciences (JBIO) Net Income towards Common Stockholders (2020 - 2026)
Jade Biosciences (JBIO) posted Net Income towards Common Stockholders of -$40.5 million for Q1 2026, down 15.65% on a QoQ basis from -$35.0 million in Q4 2025, and down 5.98% year-over-year from -$43.0 million in Q1 2025.
Jade Biosciences (JBIO) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Jade Biosciences' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$40.5 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 5.98% year-over-year to -$40.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.1 million (down 58.43% YoY) and the FY2025 annual result came in at $178000.0, up 100.26% from the prior year.
- Net Income towards Common Stockholders was -$40.5 million for Q1 2026 at Jade Biosciences, down from -$35.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$10.9 million in Q1 2022 and bottomed at -$118.1 million in Q1 2024.
- A 5-year average of -$43.4 million and a median of -$40.5 million in 2026 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 681.05% — and 2025, when it soared 67.68%.
- Jade Biosciences' Net Income towards Common Stockholders stood at -$15.8 million in 2022, then plunged by 40.57% to -$22.2 million in 2023, then plunged by 111.76% to -$47.0 million in 2024, then grew by 25.54% to -$35.0 million in 2025, then fell by 15.65% to -$40.5 million in 2026.
- Business Quant data shows JBIO's Net Income towards Common Stockholders at -$40.5 million in Q1 2026, -$35.0 million in Q4 2025, and -$56.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Jade Biosciences | 1.18 Bn | 866.20 Mn | - | -40.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.45 Mn |
| Dec 31, 2025 | -34.98 Mn |
| Sep 30, 2025 | -56.71 Mn |
| Jun 30, 2025 | -70.00 Mn |
| Mar 31, 2025 | -38.17 Mn |
| Dec 31, 2024 | -46.98 Mn |
| Sep 30, 2024 | -15.57 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Mar 31, 2024 | -118.08 Mn |
| Dec 31, 2023 | -22.19 Mn |
| Sep 30, 2023 | -39.12 Mn |
| Jun 30, 2023 | -50.25 Mn |
| Mar 31, 2023 | -60.25 Mn |
| Dec 31, 2022 | -15.78 Mn |
| Sep 30, 2022 | -48.30 Mn |
| Jun 30, 2022 | -43.85 Mn |
| Mar 31, 2022 | -10.91 Mn |
| Dec 31, 2021 | -8.22 Mn |
| Sep 30, 2021 | -6.18 Mn |
| Jun 30, 2021 | -53.21 Mn |